AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for D-beta-hydroxybutyrate dehydrogenase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q02338

UPID:

BDH_HUMAN

Alternative names:

3-hydroxybutyrate dehydrogenase; Short chain dehydrogenase/reductase family 9C member 1

Alternative UPACC:

Q02338; D3DXC0; Q96ET1; Q9BRZ4

Background:

D-beta-hydroxybutyrate dehydrogenase, mitochondrial, also known as 3-hydroxybutyrate dehydrogenase and part of the short chain dehydrogenase/reductase family 9C member 1, plays a pivotal role in ketone body metabolism. This enzyme catalyzes the reversible conversion of acetoacetate to D-beta-hydroxybutyrate in the mitochondria, a critical step in the utilization of fat as an energy source during fasting states.

Therapeutic significance:

Understanding the role of D-beta-hydroxybutyrate dehydrogenase could open doors to potential therapeutic strategies. Its involvement in energy metabolism makes it a potential target for conditions related to metabolic dysfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.